- 6.0CiteScore
- 22 daysTime to First Decision
Special Issues
Pharmaceuticals publishes Special Issues to create collections of papers on specific topics, with the aim of building a community of authors and readers to discuss the latest research and develop new ideas and research directions. Special Issues are led by Guest Editors, who are experts on the topic and all Special Issue submissions follow MDPI's standard editorial process.
The journal’s Editor-in-Chief and/or designated Editorial Board Member will oversee Guest Editor appointments and Special Issue proposals, checking their content for relevance and ensuring the suitability of the material for the journal. The papers published in a Special Issue will be collected and displayed on a dedicated page of the journal’s website. Further information on MDPI's Special Issue polices and Guest Editor responsibilities can be found here. For any inquiries related to a Special Issue, please contact the Editorial Office.
Personalized Medicine in Reproduction and Fertility
Deadline: 25 September 2026
Head and Neck Disease: Personalized Approaches to Screening and Diagnosis
Deadline: 25 September 2026
Clinical Diagnosis and Personalized Treatment in Otolaryngology
Deadline: 25 September 2026
Psychiatry: Clinical Research and Personalized Medicine
Deadline: 25 September 2026
Artificial Intelligence in Cardiovascular Diseases: Toward Personalized Diagnosis and Treatment
Deadline: 25 September 2026
Personalized Treatment and Rehabilitation for Colorectal Cancer
Deadline: 25 September 2026
Clinical Child Psychology: New Advances in Personalized Treatment and Management
Deadline: 24 September 2026
Personalized Medicine in Epidemiology and Infectious Diseases
Deadline: 20 September 2026
Personalized Medicine in Reproductive Medicine
Deadline: 20 September 2026
Assisted Reproduction: Clinical Updates and Personalized Strategies
Deadline: 15 September 2026
Personalized Medicine for Clinical Psychology
Deadline: 10 September 2026
Personalized Medicine in the ICU—2nd Edition
Deadline: 31 August 2026
of 57

